NDA 022432 · Questcor Pharma
H.P. Acthar Gel
Repository Corticotropin · Injection
Last checked: Nov 20, 2026Latest source record: Oct 15, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Oct 15, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
42
4 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 15, 2010 Original approval · Type 6 - New Indication (no longer used) LabelReviewMedication Guide
1 products under this application
- H.P. ACTHAR GEL · REPOSITORY CORTICOTROPIN 80 UNITS/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Repository Corticotropin" as an intervention, any sponsor and status, largest first.
- Acthar Gel for Active Systemic Lupus Erythematosus (SLE)Pivotal-lookingCompleted
MallinckrodtIndustry
NCT02953821 · 172 participants · Start Dec 16, 2016 · Primary completion Jul 31, 2019
Drug: Acthar Gel; Placebo Gel · For: Lupus Erythematosus, Systemic
Sites: Hemet, California; Upland, California; Fort Lauderdale, Florida · 39 sites in all
- Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingTerminated
MallinckrodtIndustry
NCT03068754 · 143 participants · Start Jun 22, 2017 · Primary completion Nov 25, 2019
Drug: Acthar; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; Scottsdale, Arizona; La Jolla, California · 69 sites in all
- Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.Not yet recruiting
Peking University People's HospitalAcademic, hospital or other
NCT07833163 · 60 participants (planned) · Start Sep 2026 · Primary completion Sep 2027
Drug: Repository Corticotropin Injection (ACTH); Study-matched inactive placebo injection, also called control injection · For: Behçet's Syndrome; Behçet's Syndrome (BS)
Sites: Beijing, China
MallinckrodtIndustry
NCT01386554 · 60 participants · Start Aug 2011 · Primary completion Nov 21, 2016
Drug: Repository Corticotropin Injection; Placebo · For: Proteinuria; Idiopathic Membranous Nephropathy
Sites: Sacramento, California; Stanford, California; Jacksonville, Florida · 28 sites in all
MallinckrodtIndustry
NCT03320070 · 55 participants · Start Feb 21, 2018 · Primary completion Nov 15, 2021
Drug: Acthar Gel; Placebo · For: Sarcoidosis, Pulmonary
Sites: Birmingham, Alabama; Los Angeles, California; Denver, Colorado · 29 sites in all
MallinckrodtIndustry
NCT01906658 · 43 participants · Start Jul 2013 · Primary completion Nov 2014
Drug: Repository corticotropin injection · For: Amyotrophic Lateral Sclerosis
Sites: Birmingham, Alabama; Phoenix, Arizona; San Francisco, California · 17 sites in all
Veena Ranganath, MD, MSAcademic, hospital or other
NCT02541955 · 40 participants · Start Jul 20, 2017 · Primary completion May 6, 2025
Drug: Acthar · For: Rheumatoid Arthritis (RA)
Sites: Los Angeles, California
Ocular Immunology and Uveitis FoundationAcademic, hospital or other
NCT03066869 · 40 participants (planned) · Start Mar 22, 2017 · Primary completion Feb 2020
Drug: H.P. ACTHAR GEL · For: Uveitis, Posterior; Vasculitis Retinal
Sites: Waltham, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Follow-up results of myositis patients treated with H. P. Acthar gel.
Saygin D, Oddis CV, Marder G, et al. · Rheumatology (Oxford) 2020 · Clinical Trial, Research Support, Non-U.S. Gov't
- Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH1-24 Depot and Methylprednisolone in Healthy Subjects.
Poola N, Due B, Wright D, et al. · Clin Pharmacol Drug Dev 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effects of Subcutaneous Repository Corticotropin Gel Injection on Regulatory T Cell Population in Noninfectious Retinal Vasculitis.
Anesi SD, Chang PY, Maleki A, et al. · Ocul Immunol Inflamm 2023 · Controlled Clinical Trial
- Efficacy and safety of repository corticotropin injection for refractory cutaneous dermatomyositis: a prospective, open-label study.
Fernandez AP, Gallop J, Polly S, et al. · Rheumatology (Oxford) 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis.
Fleischmann R, Furst DE · Expert Opin Drug Saf 2020 · Comparative Study, Systematic Review
- A Randomized Prospective Trial Comparing Repository Corticotropin Injection and Intravenous Methylprednisolone for Neuroprotection in Acute Optic Neuritis.
Bennett JL, Grove NC, Johnson RK, et al. · J Neuroophthalmol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Questcor Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.